AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04357444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2: Placebo Comparator
Description: placebo in Subcutaneous route
Study NCT02625051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopy
Description: Under general anesthesia, the patient is placed in the lithotomy position. All procedures are performed under direct videoscopic and fluoroscopic guidance. Fluoroscopic screening is utilized using a mobile multidirectional C-arm fluoroscopy unit. A safety guide-wire is then placed into renal pelvis, followed by a ureteral access sheath to maintain low intra-renal pressure, and to facilitate the procedures. Using flexible ureteroscope, renal or proximal ureteral stone is identified and fragmented with a holmium laser. Basket extraction of residual fragments is done until visual complete clearance of stone fragments is achieved.
Study NCT02625051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous nephrolithotomy
Description: Under general anesthesia, an open-ended 5 french ureteral exchange catheter is placed into the ipsilateral ureter under cystoscopic guidance. The patient is then safely turned and secured in the prone position. Percutaneous renal access is obtained under ultrasonographic or fluoroscopic guidance. Either a 24 or 30 french sheath is advanced in the kidney and nephroscopy is performed with a rigid offset nephroscope. Stone fragmentation is accomplished using a dual CyberWand lithotripter or holmium laser lithotripsy. Flexible nephroscopy is performed to look for possible residual fragments and basket extraction is done for complete clearance of stone.
Study NCT03543657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: Starting dose of molidustat will be titrated based on the subject's Hb (Hemoglobin) response. Administrated orally once daily (OD).
Study NCT03543657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Starting dose of darbepoetin alfa will be titrated based on the subject's Hb (Hemoglobin) response. Administrated weekly or once every two weeks by intravenous injection.
Study NCT03543657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Molidustat (BAY85-3934)
Description: Matching placebo of Molidustat.
Study NCT01729299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyl ghrelin
Study NCT01729299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study NCT02486536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Study NCT03543657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Darbepoetin alfa
Description: Matching placebo of Darbepoetin alfa.
Study NCT01792050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel chemotherapy regimen given by vein over 1 hour on day 8 of each cycle.
Study NCT01792050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel chemotherapy regimen given by vein over 1 hour on day 8 of each cycle.
Study NCT01792050 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six pills to be taken each time for a total of 12 pills per day.
Study NCT01792050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod (1200 mg) taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six 200 mg pills to be taken twice a day for a total of 12 pills per day.
Study NCT01792050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel chemotherapy regimen given by vein over 1 hour weekly x 3 followed by a week of rest each cycle.
Study NCT01792050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel chemotherapy regimen given by vein over 1 hour weekly x 3 followed by a week of rest each cycle.
Study NCT05333952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
Study NCT05333952 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pulmonary vein isolation
Description: The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
Study NCT02486536 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: capsule endoscopy
Study NCT05333952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Substrate ablation(PRISM based)
Description: Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
Study NCT01770106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Subcutaneous injection of denosumab 60mg every 6 months (1 dose for study period)
Study NCT01770106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70mg once weekly
Study NCT01459484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifamurtide arm
Description: PRE SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~POST SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~All the product are used as commercial formulation
Study NCT01459484 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3 drugs arm
Description: High grade osteosarcoma who do not over express ABCB1/P-glycoprotein will be treated with a standard 3-drugs regimen~PRE-SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT:~Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2~Total lenght 34 weeks~All the product are used as commercial formulation
Study NCT02029872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate soap
Description: 4% chlorhexidine gluconate (soap)
Study NCT02029872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate oral rinse
Description: chlorhexidine gluconate oral rinse 0.12%
Study NCT02029872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin calcium 2 % ointment
Description: nasal mupirocin calcium 2% ointment
Study NCT01579227 — intervention group
Intervention type: DEVICE
Intervention: Topical Tocotrienol (TCT)
Description: Natural Form Vitamin E topical cream(TCT)
Study NCT02384265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IM/SMS + Incentive Condition
Description: See description of Intervention arm protocols above.
Study NCT03951506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-modal exercise program
Description: Each session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk,one-leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking. Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
Study NCT03951506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Each session (48) consist in isotonic exercises of low intensity and joint mobility of the lower extremities. These exercises are usually prescribed in medical consultations for the treatment of knee osteoarthritis.
Study NCT04480138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-α2b
Description: 1 mcg/kg on day 1 and day 8 after safety evaluations.
Study NCT04480138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care as per local authority
Study NCT04480138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care as per local authority
Study NCT01303484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 5.5g daily for 10 weeks
Study NCT00718601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat Sodium (GRN163L)
Description: 25% dose escalation infused over 2 hours weekly
Study NCT02188160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121
Description: KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Study NCT02188160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Study NCT04432480 — intervention group
Intervention type: PROCEDURE
Intervention: NIPE (Newborn Infant Parasympathetic Evaluation) monitoring
Description: Non invasive monitor connected to standard anesthesia monitor (no part of the device in contact with the patient) during anesthesia.
Study NCT01474343 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SAF-301
Description: The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.
Study NCT03440320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MY-SKILLS - online
Description: Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of yoga and an hour of self-management designed to meet the needs of a caregiving dyad with chronic pain
Study NCT03440320 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MY-Plan control - online
Description: Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain..
Study NCT00379405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours
Description: Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours
Study NCT04734613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: Yang style Tai Chi 16 movements
Study NCT04734613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self management
Description: health education and dietary counseling
Study NCT03272204 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No pubic hair
Description: Natural pubic hair to fully removed pubic hair
Study NCT03272204 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pubic Hair
Description: Removed pubic hair to natural pubic hair
Study NCT02059109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hands on Assembly of Belmont Rapid Infuser
Description: Participants will work individually or in pairs to assemble the Belmont Rapid Infuser in addition to completing the traditional training methods.
Study NCT00863122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1500 mg lapatinib by mouth per day for 10 days
Study NCT02442908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrifriend Cachexia
Description: 2 daily for 12 weeks
Study NCT02442908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric placebo
Description: 2 daily for 12 weeks
Study NCT01899092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-034
Description: The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given.
Study NCT01579227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Oral Tocotrienol Capsules (TCT)
Description: Natural Form Vitamin E Oral capsules (TCT)
Study NCT02441231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visbiome
Description: Visbiome probiotic
Study NCT02441231 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01579227 — intervention group
Intervention type: DEVICE
Intervention: Tamoxifen Cream
Description: Tamoxifen cream
Study NCT01579227 — intervention group
Intervention type: DEVICE
Intervention: Placebo cream
Description: Placebo cream
Study NCT01579227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: placebo capsule
Description: placebo capsule
Study NCT03962179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VACStent
Description: Evaluation of the suitability of the medical device for sealing leaks in the gastrointestinal tract
Study NCT00890825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD6244
Description: oral capsules, 75mg twice daily
Study NCT01167764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tranexamic acid, placebo
Description: tranexamic acid 250mg tid for 1 months vs. placebo for 1 months
Study NCT01167764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid, placebo
Description: tranexamic acid 250mg tid for 1 months vs. placebo for 1 months
Study NCT00890825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75mg/m2 iv on day 1 of every 21 day cycle
Study NCT00890825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docetaxel
Description: 75mg/m2 iv on day 1 of every 21 day cycle
Study NCT00890825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01508169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot orthosis (Orthotics Unit of the Clinical Hospital of UNICAMP)
Description: Custom foot orthoses made of ethylene-vinyl acetate (EVA) with medial arch supports and metatarsal pads (supporting the diaphysis of the second to fourth metatarsals) that were manufactured by the Orthotics and Prostheses Unit of the Clinical Hospital of UNICAMP.
Study NCT03659799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin FiAsp
Description: An insulin bolus of FiAsp will be given 5 minutes before breakfast
Study NCT03659799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: An insulin bolus of Aspart will be given 5 minutes before breakfast
Study NCT03659799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 60-minutes postprandial exercise
Description: A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast
Study NCT03659799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 120-minutes postprandial exercise
Description: A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast
Study NCT04035252 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid artery reactivity test (CAR-test)
Description: The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved. During this test as well the carotid artery as the abdominal aorta will be visualized using ultrasound.
Study NCT00806910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conivaptan
Description: IV Vaprisol initially at 20 mg IV injection over 30 minutes, followed by a 20 mg IV infusion over the next 24 hours (i.e. 20 mg bolus, 20 mg continuous infusion approximately 24 hrs).
Study NCT00806910 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (will be given at the same rate of Vaprisol given in the treatment arm)
Study NCT03200834 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right Hemicolectomy with D2 lymph node dissection
Description: Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).
Study NCT03200834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right Hemicolectomy with D3 lymph node dissection
Description: Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).
Study NCT03195816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive training
Description: Experimental group will receive 1 year of a computer-based cognitive stimulation program, first 6 months, 60-minutes twice a week and next 6 months once a week training in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
Study NCT00988884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm at Day 1, Month 2, and Month 6
Study NCT00988884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Menactra™ (Concomitant)
Description: Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
Study NCT00988884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Adacel™ (Concomitant)
Description: Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
Study NCT00988884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Menactra™ (Non-Concomitant)
Description: Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
Study NCT00988884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Adacel™ (Non-concomitant)
Description: Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
Study NCT03865082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilsotolimod
Description: 9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Week 0 Day 1 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7.
Study NCT03865082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days.
Study NCT03865082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days.